LONDON, April 7 (Reuters) - Britain's recommendation against
giving the Oxford-AstraZeneca COVID-19 vaccine to those
aged under 30 due to the risk of blood clots will have a
negligible impact on the vaccine programme, England's deputy
chief medical officer Jonathan Van-Tam said.
"Because of our supply situation in relation to alternative
vaccines, the effect on the timing of our overall programme
should be zero or negligible," he said at a briefing on
Wednesday.
(Reporting by Guy Faulconbridge and Kate Holton, Writing by
Paul Sandle; editing by James Davey)